Heparin Market Size and Forecast 2024-2033|Baxter International Inc., B. Braun Medical Inc., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leo Pharma A/S,

Close-up of a senior male patient administering daily intravenous infusion to himself of saline, antibiotics and heparin through a PICC line. Real people. Real life. This patient was in the hospital for with MRSA and sepsis.

Overview and Scope

Heparin refers to an anticoagulant type substance that slows the development of blood clots. Heparin is produced by the liver, lungs, and other human tissues, but it can also be produced in a lab. In order to prevent or dissolve blood clots, heparin may be injected into muscle or blood. Heparin is widely used in hospitals to prevent excessive coagulation during cardiac surgery, extracorporeal circulation, or dialysis.

Sizing and Forecast

The heparin market size has grown strongly in recent years. It will grow from $9.29 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, advances in surgical procedures requiring anticoagulation, growth in the aging population, rise in deep vein thrombosis cases, expansion of applications in renal dialysis.

The heparin market size is expected to see strong growth in the next few years. It will grow to $12.92 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for low-molecular-weight heparin, expansion of heparin use in the treatment of cancer, increasing incidence of venous thromboembolism, development of biosynthetic heparin, increase in the number of emerging markets. Major trends in the forecast period include technological advancements in heparin production, emphasis on the production of safer and more bioavailable heparin, integration of digital technologies in heparin administration, adoption of biosimilars, exploration of heparin alternatives and substitutes.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/heparin-global-market-report

Segmentation & Regional Insights

The heparin market covered in this report is segmented –

1) By Product: Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)

2) By Source: Bovine, Porcine

3) By Route of Administration: Intravenous, Subcutaneous

4) By Application: Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies

North America was the largest region in the heparin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heparin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6684&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of chronic diseases is significantly driving the growth of the heparin market. Chronic diseases refer to medical conditions, which last more than one year and require constant medical attention or hospitalization for specialized treatment. The changing lifestyle, eating habits, and inappropriate maintenance of body weight are the reasons for chronic conditions and a few more prolonged chronic infections lead to cancerous risk. Growing exposure to the disease has increased the demand for heparin, as they are widely used to make the blood thin during surgeries and various medical treatments. For instance, in July 2021, according to the International Diabetes Federation (IDF), a Belgium-based diabetes organization, the number of persons with diabetes worldwide is predicted to reach 537 million in 2021, 643 million in 2030, and 783 million in 2045. In addition, it was anticipated that 541 million people would have impaired glucose tolerance by 2021. Additionally, it is anticipated that in 2021, nearly 6.7 million people between the ages of 20 and 79 will pass away due to complications from diabetes. Therefore, the increasing prevalence of chronic diseases will drive the growth of the heparin market.

Key Industry Players

Major companies operating in the heparin market report are Baxter International Inc., B. Braun Medical Inc., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leo Pharma A/S, Aspen Pharmacare plc, Bioiberica SA, Biomedical Foscama Group, Biovet SA, Changzhou Qianhong Bio-pharma Co. Ltd., CSPC NBP Pharmaceutical Co. Ltd., Gelita Medical AG, Intas Pharmaceuticals Ltd., Nanjing King-friend Biochemical Pharmaceutical Co. Ltd., Opocrin Pharmaceuticals Ltd., Pfizer Inc., Pharma Action Ltd., Rovi Pharma Industrial Services Ltd., Sagent Pharmaceuticals Inc., Sanofi S. A., Shenzhen Hepalink Pharmaceutical Co. Ltd., Sichuan Deebio Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., VAV Life Sciences Inc., Viatris Inc., Wanbang Biopharmaceuticals Co. Ltd., Wockhardt Ltd., Xinbai Pharmaceuticals Co. Ltd., Yino Pharma Co. Ltd., TEGA Therapeutics Inc.

The heparin market report table of contents includes:

1. Executive Summary

2. Heparin Market Characteristics

3. Heparin Market Trends And Strategies

4. Heparin Market – Macro Economic Scenario

5. Global Heparin Market Size and Growth

26. South America Heparin Market

27. Brazil Heparin Market

28. Middle East Heparin Market

29. Africa Heparin Market

30. Heparin Market Competitive Landscape And Company Profiles

Top Major Players: